SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : VOLTAIRE'S PORCH-MODERATED -- Ignore unavailable to you. Want to Upgrade?

To: Sully- who wrote (59562)10/30/2003 5:09:40 PM
From: Cactus Jack  Respond to of 65232
 
wstera,

My brother was a sales rep for Pfizer when Vioxx and Celebrex came to market a few years back. He said that the overwhelming evidence indicated that Vioxx couldn't hold a candle to Celebrex and had significant side effects that Celebrex didn't have. When I asked him how Vioxx would be able to compete if he was right, he laughed and replied "Because Merck is the best marketing machine". Based on that (marketing) alone, he still owns Merck stock.

True story. Ask your doc about Celebrex.

jpg



To: Sully- who wrote (59562)10/30/2003 10:06:45 PM
From: elpolvo  Read Replies (1) | Respond to of 65232
 
OOFie-

this may sound stupid, but i prefer to call
it "thinking outside the box"...

find out what limbaugh was taking. he strikes
me as yer typical "type A" hypertensive personality
who was also quite overweight until recently and
probably had high cholesterol readings too. if he
didn't have a heart attack with all those risk
factors, chances are, you won't either.

one caveat... beware the addictive properties of
whatever he was abusing.

:-)

-polvo


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News